Sato K, Fujii Y, Kasono K, Ozawa M, Imamura H, Kanaji Y, Kurosawa H, Tsushima T, Shizume K
Institute of Clinical Endocrinology, Tokyo Women's Medical College, Japan.
Endocrinology. 1989 May;124(5):2172-8. doi: 10.1210/endo-124-5-2172.
To elucidate the mechanism of humoral hypercalcemia elicited by human esophageal carcinoma cells (EC-GI), which constitutively produced interleukin-1 alpha (IL-1 alpha) and PTH-like factor, the effects of IL-1 alpha and PTH-related protein (PTH-rP) on bone resorption in vitro and on serum calcium concentrations in vivo were investigated. Nude mice transplanted with EC-GI cells invariably developed hypercalcemia, although their urinary cAMP excretion remained within the normal range. IL-1 alpha or PTH-rP-(1-34) stimulated 45Ca release from prelabeled fetal mouse forearm bones in a concentration-dependent manner, and when combined, IL-1 alpha and PTH-rP-(1-34) synergistically stimulated bone resorption in vitro. Injection of PTH-rP-(1-34) into mice three times a day for 2 days increased the serum calcium concentration in a dose-dependent manner. Continuous infusion of IL-1 alpha occasionally increased the serum calcium concentration. Simultaneous administration of IL-1 alpha at rates of 1-2.7 micrograms/day and PTH-rP-(1-34) at doses of 15-30 micrograms/day synergistically increased the serum calcium concentration in vivo. These findings suggest that PTH-rP and IL-1 alpha produced by the tumor cells were synergistically responsible for the humoral hypercalcemia observed in both the original patient and the tumor-bearing nude mice, and that at least two bone-resorbing factors [PTH-rP and another nonadenylate cyclase-stimulating bone-resorbing factor(s)] are active in patients with malignancy-associated hypercalcemia, in whom nephrogenous cAMP excretion is neither increased nor decreased.
为阐明人食管癌细胞(EC-GI)引发体液性高钙血症的机制,该细胞可组成性产生白细胞介素-1α(IL-1α)和甲状旁腺激素样因子,研究了IL-1α和甲状旁腺激素相关蛋白(PTH-rP)对体外骨吸收及体内血清钙浓度的影响。移植了EC-GI细胞的裸鼠均出现高钙血症,但其尿中环磷酸腺苷(cAMP)排泄仍在正常范围内。IL-1α或PTH-rP-(1-34)以浓度依赖的方式刺激预先标记的胎鼠前臂骨释放45Ca,并且联合使用时,IL-1α和PTH-rP-(1-34)在体外协同刺激骨吸收。每天给小鼠注射3次PTH-rP-(1-34),持续2天,血清钙浓度呈剂量依赖性增加。持续输注IL-1α偶尔会使血清钙浓度升高。以1-2.7微克/天的速率同时给予IL-1α和以15-30微克/天的剂量给予PTH-rP-(1-34)在体内协同增加血清钙浓度。这些发现表明,肿瘤细胞产生的PTH-rP和IL-1α协同导致了在原患者和荷瘤裸鼠中观察到的体液性高钙血症,并且至少两种骨吸收因子[PTH-rP和另一种非腺苷酸环化酶刺激的骨吸收因子]在恶性肿瘤相关性高钙血症患者中起作用,这些患者的肾源性cAMP排泄既不增加也不减少。